Summary
A phase II trial of 4′ Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four responses, all partial, were observed in 35 evaluable patients, for a response rate of 11% (95% confidence limits 3.2% and 26.7%). Myelosuppression was the dose-limiting toxicity. Cardiotoxicity was not seen. DXDX has minimal activity against non-small cell lung cancer as a single agent at the dosage used in this study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Casazza AM, Savi G, Pratesi G, DiMarco A: Antitumor activity in mice of 4′ deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clinical Oncology 191:291, 1983
Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40:4682, 1980
Minutes of the Phase I Meeting. Investigational Drug Branch, National Cancer Institute. September 19–20, 1983
Sarosy G: Memorandum from National Cancer Institute. November 8, 1985
Oken MM, Creech RH, Tormey DP, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria for the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
Kaplan S, Sessa R, Obrecht JP, Joss R, Siegenthaler P, Cavalli F: Phase II trial of 4′ deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 69:1337–1338, 1985
Kris MG, Gralla RJ, Burke MT, Fiore JJ, Kelsen DP, Marks LD, Heelan RT: Phase II trial of esorubicin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 71:783–784, 1987
Conley B, Hornedo J, Abrams J, Eisenberger M, Hiponia D, Aisner J, Van Echo DA: Phase II trial of 4′ deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 71:861–862, 1987
Author information
Authors and Affiliations
Additional information
Supported in part by Public Health Service Grant CA-21742 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services
Rights and permissions
About this article
Cite this article
Rose, C., Lad, T.E., Kilton, L.J. et al. Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. Invest New Drugs 8, 97–99 (1990). https://doi.org/10.1007/BF00216932
Issue Date:
DOI: https://doi.org/10.1007/BF00216932